

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously Presented) A kit comprising firstly a lyophilized didemnin preparation comprising water-soluble material and secondly, and separately contained, a reconstitution solution of mixed solvents.
2. (Previously Presented) A kit according to claim 1, wherein the kit comprises an amount of the lyophilized didemnin preparation that is suitable for the treatment of a tumor in a patient.
3. (Previously Presented) A kit according to claim 1, wherein the didemnin compound is selected from didemnins, dehydroididemnins, nordidemnins, didemnin congeners and didemnin analogs.
4. (Previously Presented) A kit according to claim 3, wherein the didemnin is aplidine.
5. (Previously Presented) A kit according to any of the preceding claims, wherein the reconstitution solution comprises an alkanol/water mix.
6. (Previously Presented) A kit according to claim 5, wherein the reconstitution solution further comprises a nonionic surfactant.
7. (Previously Presented) A kit according to claim 6, wherein the nonionic surfactant is 10 to 25% v/v of the solution; the alkanol is ethanol and is 10 to 25% v/v of the solution; and the water is 50 to 80% v/v of the solution.

8. (Previously Presented) A kit according to claim 1, which comprises a vial of lyophilized didemnin preparation comprising a water-soluble bulking agent, and a separate vial of a premix of non-ionic surfactant/ethanol/water.
9. (Withdrawn) A method of preparing a pharmaceutical composition of a didemnin compound, which comprises freeze drying a didemnin/water-soluble additive/alkanol/water mix to provide a lyophilized first component, and separately providing an alkanol/water mix as reconstitution solution.
10. (Withdrawn) A method according to claim 9 wherein the alkanol in the mix is t-butanol.
11. (Withdrawn) A method according to claim 9 or 10 wherein the amount of alkanol in the alkanol/water mix is 25 to 60% v/v.
12. (Previously Presented) A reconstituted pharmaceutical composition comprising:
 - a didemnin compound;
 - a water soluble material;
 - a surfactant;
 - an alkanol; and
 - water.
13. (Previously Presented) The pharmaceutical composition of claim 12, wherein the water soluble material is a water soluble bulking agent.
14. (Previously Presented) The pharmaceutical composition of claim 13, wherein the water soluble water soluble bulking agent is mannitol.
15. (Previously Presented) The pharmaceutical composition of claim 12, wherein the didemnin compound is selected from the group consisting of a didemnin, a dehydrodidemnin, a nordidemnin, a didemnin congener or a didemnin analog.

16. (Previously Presented) The pharmaceutical composition of claim 15, where in the didemninn compound is aplidine.

17. (Previously Presented) The pharmaceutical composition of claim 12, wherein the surfactant is a nonionic surfactant.

18. (Previously Presented) The pharmaceutical composition of claim 17, wherein the nonionic surfactant is Cremophor EL.

19. (Previously Presented) The pharmaceutical composition of claim 12, wherein the alkanol is ethanol.

20. (Previously Presented) The pharmaceutical composition of claim 12, wherein the composition is prepared by the steps comprising:

(i) freeze drying a first solution comprising the didemninn compound, the water-soluble material and an alkanol/water mix to provide a lyophilized didemninn preparation; and

(ii) reconstituting the lyophilized didemninn preparation with a nonionic surfactant/alkanol/water mix to form a second solution.

21. (Previously Presented) The pharmaceutical composition of claim 20, wherein the alkanol/water mix comprises *t*-butanol.

22. (Previously Presented) The pharmaceutical composition of claim 21, wherein the alkanol/water mix comprises 25 to 60% v/v *t*-butanol.

23. (Previously Presented) The pharmaceutical composition of claim 20, wherein the nonionic surfactant is 10 to 25% v/v of the nonionic surfactant/alkanol/water mix; the alkanol is ethanol and is 10 to 25% v/v of the nonionic surfactant/alkanol/water mix; and the water is 50 to 80% v/v of the nonionic surfactant/alkanol/water mix.

24. (Previously Presented) A lyophilized didemninn preparation prepared by freeze drying a solution comprising a didemninn compound, a water-soluble material and an alkanol/water mix.
25. (Previously Presented) A pharmaceutical composition prepared by reconstituting the lyophilized didemninn preparation of claim 24 with a nonionic surfactant/alkanol/water mix.
26. (Previously Presented) A kit according to claim 1, which comprises a vial of lyophilized didemninn preparation comprising a water-soluble material, and a separate vial of a reconstitution solution of mixed solvents.
27. (Previously Presented) A kit according to claim 1, wherein the didemninn is a dehydrodidemninn.
28. (Previously Presented) The pharmaceutical composition according to claim 12, wherein the didemninn is a dehydrodidemninn.
29. (New) An intravenous delivery device having disposed therein: a didemninn compound; a water soluble material; a surfactant; an alkanol; and water.
30. (New) A method for delivering a didemninn compound, the method comprising filling an intravenous delivery device with a didemninn compound; a water soluble material; a surfactant; an alkanol; and water.